Skip to main content
Top
Published in: Current Diabetes Reports 5/2014

01-05-2014 | Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

Diabetes and Hemochromatosis

Authors: T. Creighton Mitchell, Donald A. McClain

Published in: Current Diabetes Reports | Issue 5/2014

Login to get access

Abstract

The common form of hereditary hemochromatosis is an autosomal recessive disorder most prevalent in Caucasians that results in excessive iron storage. The clinical manifestations of hemochromatosis are protean. HFE genotype, which determines the degree of iron overload and duration of disease have profound effects on disease expression. The prevalence of diabetes in this population has likely been underestimated because of studies that include a broad range of ethnicities and associating diabetes with allele frequency in spite of the decreased risk of diabetes in heterozygotes compared with homozygotes. Loss of insulin secretory capacity is likely the primary defect contributing to development of diabetes with insulin resistance playing a secondary role. Phlebotomy can ameliorate the defects in insulin secretion if initiated early. Screening a select population of individuals with type 2 diabetes may identify patients with hemochromatosis early and substantially impact individual clinical outcomes.
Literature
1.••
go back to reference Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393–408. 408.e1-2. A comprehensive review of all clinical aspects of hemochromatosis. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393–408. 408.e1-2. A comprehensive review of all clinical aspects of hemochromatosis.
2.
go back to reference Federer JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399–408.CrossRef Federer JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399–408.CrossRef
3.
go back to reference Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3.PubMedCrossRef Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3.PubMedCrossRef
5.
go back to reference Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol. 1997;92(5):784–9.PubMed Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol. 1997;92(5):784–9.PubMed
6.
go back to reference Neghina AM, Anghel A. Hemochromatosis genotypes and risk of iron overload–a meta-analysis. Ann Epidemiol. 2011;21(1):1–14.PubMedCrossRef Neghina AM, Anghel A. Hemochromatosis genotypes and risk of iron overload–a meta-analysis. Ann Epidemiol. 2011;21(1):1–14.PubMedCrossRef
7.
go back to reference Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G– > A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359(9302):211–8.PubMedCrossRef Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G– > A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359(9302):211–8.PubMedCrossRef
8.
go back to reference Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343(21):1529–35.PubMedCrossRef Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343(21):1529–35.PubMedCrossRef
9.
go back to reference Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–30.PubMedCrossRef Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–30.PubMedCrossRef
10.
go back to reference Lainé F, Jouannolle AM, Morcet J, Brigand A, Pouchard M, Lafraise B, et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol. 2005;43(6):1055–9.PubMedCrossRef Lainé F, Jouannolle AM, Morcet J, Brigand A, Pouchard M, Lafraise B, et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol. 2005;43(6):1055–9.PubMedCrossRef
11.
go back to reference Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008;135(6):1945–52.PubMedCrossRef Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008;135(6):1945–52.PubMedCrossRef
12.
go back to reference Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107–19.PubMedCrossRef Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107–19.PubMedCrossRef
14.
go back to reference Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care. 2006;29(9):2084–9.PubMedCrossRef Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care. 2006;29(9):2084–9.PubMedCrossRef
15.
go back to reference Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103(8):2914–9.PubMedCrossRef Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103(8):2914–9.PubMedCrossRef
16.
go back to reference Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care. 2001;24(7):1187–91.PubMedCrossRef Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care. 2001;24(7):1187–91.PubMedCrossRef
17.
go back to reference Kwan T, Leber B, Ahuja S, Carter R, Gerstein HC. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med. 1998;21(6):251–7.PubMed Kwan T, Leber B, Ahuja S, Carter R, Gerstein HC. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med. 1998;21(6):251–7.PubMed
18.
go back to reference Salonen JT, Tuomainen TP, Kontula K. Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. BMJ. 2000;320(7251):1706–7.PubMedCentralPubMedCrossRef Salonen JT, Tuomainen TP, Kontula K. Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. BMJ. 2000;320(7251):1706–7.PubMedCentralPubMedCrossRef
19.
go back to reference Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001;358(9291):1405–9.PubMedCrossRef Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001;358(9291):1405–9.PubMedCrossRef
20.
go back to reference Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ, et al. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case - control study. Hum Mol Genet. 2003;12(12):1361–5.PubMedCrossRef Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ, et al. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case - control study. Hum Mol Genet. 2003;12(12):1361–5.PubMedCrossRef
21.
go back to reference Rong Y, Bao W, Rong S, Fang M, Wang D, Yao P, et al. Hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a meta-analysis. Am J Epidemiol. 2012;176(6):461–72.PubMedCrossRef Rong Y, Bao W, Rong S, Fang M, Wang D, Yao P, et al. Hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a meta-analysis. Am J Epidemiol. 2012;176(6):461–72.PubMedCrossRef
22.
go back to reference Qi L, Meigs J, Manson JE, Ma J, Hunter D, Rifai N, et al. HFE genetic variability, body iron stores, and the risk of type 2 diabetes in U.S. women. Diabetes. 2005;54(12):3567–72.PubMedCrossRef Qi L, Meigs J, Manson JE, Ma J, Hunter D, Rifai N, et al. HFE genetic variability, body iron stores, and the risk of type 2 diabetes in U.S. women. Diabetes. 2005;54(12):3567–72.PubMedCrossRef
23.•
go back to reference Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ, et al. Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism. 2010;59(3):380–4. Detailed assessment of glucose metabolism in individuals with HH. PubMedCrossRef Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ, et al. Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism. 2010;59(3):380–4. Detailed assessment of glucose metabolism in individuals with HH. PubMedCrossRef
24.•
go back to reference McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia. 2006;49(7):1661–9. Provides an estimate of the prevalence of diabetes in HH unbiased by preexisting diabetes. Evidence that insulin secretion is the primary defect causing diabetes in HH. PubMedCrossRef McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia. 2006;49(7):1661–9. Provides an estimate of the prevalence of diabetes in HH unbiased by preexisting diabetes. Evidence that insulin secretion is the primary defect causing diabetes in HH. PubMedCrossRef
25.
go back to reference Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–78.PubMedCrossRef Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–78.PubMedCrossRef
26.
go back to reference O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH, et al. Declining prevalence of diabetes mellitus in hereditary haemochromatosis–the result of earlier diagnosis. Diabetes Res Clin Pract. 2008;81(3):316–20.PubMedCrossRef O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH, et al. Declining prevalence of diabetes mellitus in hereditary haemochromatosis–the result of earlier diagnosis. Diabetes Res Clin Pract. 2008;81(3):316–20.PubMedCrossRef
27.•
go back to reference Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–43. Practice guidelines for management of hemochromatosis. Discusses screening in individuals with liver disease. PubMedCentralPubMedCrossRef Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–43. Practice guidelines for management of hemochromatosis. Discusses screening in individuals with liver disease. PubMedCentralPubMedCrossRef
28.
go back to reference Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999;22(12):1978–83.PubMedCrossRef Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999;22(12):1978–83.PubMedCrossRef
29.
go back to reference Cheung CL, Cheung TT, Lam KS, Cheung BM. High ferritin and low transferrin saturation are associated with pre-diabetes among a national representative sample of U.S. adults. Clin Nutr. 2013;32(6):1055–60.PubMedCrossRef Cheung CL, Cheung TT, Lam KS, Cheung BM. High ferritin and low transferrin saturation are associated with pre-diabetes among a national representative sample of U.S. adults. Clin Nutr. 2013;32(6):1055–60.PubMedCrossRef
30.
go back to reference R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004;291(6):711–7. R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004;291(6):711–7.
31.
go back to reference Aregbesola A, Voutilainen S, Virtanen JK, Mursu J, Tuomainen TP. Body iron stores and the risk of type 2 diabetes in middle-aged men. Eur J Endocrinol. 2013;169(2):247–53.PubMedCrossRef Aregbesola A, Voutilainen S, Virtanen JK, Mursu J, Tuomainen TP. Body iron stores and the risk of type 2 diabetes in middle-aged men. Eur J Endocrinol. 2013;169(2):247–53.PubMedCrossRef
32.
go back to reference Zhao Z, Li S, Liu G, Yan F, Ma X, Huang Z, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012;7(7):e41641.PubMedCentralPubMedCrossRef Zhao Z, Li S, Liu G, Yan F, Ma X, Huang Z, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012;7(7):e41641.PubMedCentralPubMedCrossRef
33.
go back to reference Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev. 2013;29(4):308–18.PubMedCrossRef Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev. 2013;29(4):308–18.PubMedCrossRef
34.
go back to reference Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci. 2003;325(6):332–9.PubMedCrossRef Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci. 2003;325(6):332–9.PubMedCrossRef
35.
go back to reference Afkhami-Ardekani M, Rashidi M. Iron status in women with and without gestational diabetes mellitus. J Diabetes Complicat. 2009;23(3):194–8.PubMedCrossRef Afkhami-Ardekani M, Rashidi M. Iron status in women with and without gestational diabetes mellitus. J Diabetes Complicat. 2009;23(3):194–8.PubMedCrossRef
36.
go back to reference Sharifi F, Nasab NM, Zadeh HJ. Elevated serum ferritin concentrations in prediabetic subjects. Diabetes Vasc Dis Res. 2008;5(1):15–8.CrossRef Sharifi F, Nasab NM, Zadeh HJ. Elevated serum ferritin concentrations in prediabetic subjects. Diabetes Vasc Dis Res. 2008;5(1):15–8.CrossRef
37.
go back to reference Bao W, Rong Y, Rong S, Liu L. Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med. 2012;10:119.PubMedCentralPubMedCrossRef Bao W, Rong Y, Rong S, Liu L. Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med. 2012;10:119.PubMedCentralPubMedCrossRef
38.
go back to reference Rajpathak S, Ma J, Manson J, Willett WC, Hu FB. Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care. 2006;29(6):1370–6.PubMedCrossRef Rajpathak S, Ma J, Manson J, Willett WC, Hu FB. Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care. 2006;29(6):1370–6.PubMedCrossRef
39.
go back to reference Lee DH, Folsom AR, Jacobs Jr DR. Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia. 2004;47(2):185–94.PubMedCrossRef Lee DH, Folsom AR, Jacobs Jr DR. Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia. 2004;47(2):185–94.PubMedCrossRef
40.
go back to reference Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta. 2009;1790(7):671–81.PubMedCrossRef Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta. 2009;1790(7):671–81.PubMedCrossRef
41.
go back to reference Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227–31.PubMedCrossRef Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227–31.PubMedCrossRef
42.
go back to reference Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6 Suppl 1:158–69.PubMed Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6 Suppl 1:158–69.PubMed
43.
go back to reference Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997;20(2):110–8.PubMed Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997;20(2):110–8.PubMed
44.
go back to reference Kishimoto M, Endo H, Hagiwara S, Miwa A, Noda M. Immunohistochemical findings in the pancreatic islets of a patient with transfusional iron overload and diabetes: case report. J Med Invest. 2010;57(3–4):345–9.PubMedCrossRef Kishimoto M, Endo H, Hagiwara S, Miwa A, Noda M. Immunohistochemical findings in the pancreatic islets of a patient with transfusional iron overload and diabetes: case report. J Med Invest. 2010;57(3–4):345–9.PubMedCrossRef
45.•
go back to reference Cooksey RC, Jouihan HA, Ajioka RS, Hazel MW, Jones DL, Kushner JP, et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology. 2004;145(11):5305–12. Comprehensive study of glucose homeostasis and failure of insulin secretion in a mouse model of HFE hemochromatosis. PubMedCrossRef Cooksey RC, Jouihan HA, Ajioka RS, Hazel MW, Jones DL, Kushner JP, et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology. 2004;145(11):5305–12. Comprehensive study of glucose homeostasis and failure of insulin secretion in a mouse model of HFE hemochromatosis. PubMedCrossRef
46.
go back to reference Jouihan HA, Cobine PA, Cooksey RC, Hoagland EA, Boudina S, Abel ED, et al. Iron-mediated inhibition of mitochondrial manganese uptake mediates mitochondrial dysfunction in a mouse model of hemochromatosis. Mol Med. 2008;14(3–4):98–108.PubMedCentralPubMed Jouihan HA, Cobine PA, Cooksey RC, Hoagland EA, Boudina S, Abel ED, et al. Iron-mediated inhibition of mitochondrial manganese uptake mediates mitochondrial dysfunction in a mouse model of hemochromatosis. Mol Med. 2008;14(3–4):98–108.PubMedCentralPubMed
47.
go back to reference Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348–54.PubMedCrossRef Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348–54.PubMedCrossRef
48.
go back to reference Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277(29):25863–6.PubMedCrossRef Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277(29):25863–6.PubMedCrossRef
49.
go back to reference Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012;122(10):3529–40.PubMedCentralPubMedCrossRef Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012;122(10):3529–40.PubMedCentralPubMedCrossRef
50.
go back to reference Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr. 2008;88(5):1213–24.PubMed Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr. 2008;88(5):1213–24.PubMed
51.
go back to reference Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50(5):949–56.PubMedCrossRef Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50(5):949–56.PubMedCrossRef
52.
go back to reference Mojiminiyi OA, Marouf R, Abdella NA. Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008;18(8):559–66.PubMedCrossRef Mojiminiyi OA, Marouf R, Abdella NA. Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008;18(8):559–66.PubMedCrossRef
53.
go back to reference Abraham D, Rogers J, Gault P, Kushner JP, McClain DA. Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia. 2006;49(11):2546–51.PubMedCrossRef Abraham D, Rogers J, Gault P, Kushner JP, McClain DA. Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia. 2006;49(11):2546–51.PubMedCrossRef
54.
go back to reference Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism. 2010;59(12):1811–5.PubMedCrossRef Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism. 2010;59(12):1811–5.PubMedCrossRef
55.
go back to reference Equitani F, Fernandez-Real JM, Menichella G, Koch M, Calvani M, Nobili V, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care. 2008;31(1):3–8.PubMedCrossRef Equitani F, Fernandez-Real JM, Menichella G, Koch M, Calvani M, Nobili V, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care. 2008;31(1):3–8.PubMedCrossRef
56.
go back to reference Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. Diabetes Care. 2008;31(3):e18.PubMedCrossRef Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. Diabetes Care. 2008;31(3):e18.PubMedCrossRef
57.
go back to reference Peterlin B, Globocnik Petrovic M, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. J Hum Genet. 2003;48(12):646–9.PubMedCrossRef Peterlin B, Globocnik Petrovic M, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. J Hum Genet. 2003;48(12):646–9.PubMedCrossRef
58.
go back to reference Oliva R, Novials A, Sánchez M, Villa M, Ingelmo M, Recasens M, et al. The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. Endocrine. 2004;24(2):111–4.PubMedCrossRef Oliva R, Novials A, Sánchez M, Villa M, Ingelmo M, Recasens M, et al. The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. Endocrine. 2004;24(2):111–4.PubMedCrossRef
59.
go back to reference Davis TM, Beilby J, Davis WA, Olynyk JK, Jeffrey GP, Rossi E, et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2008;31(9):1795–801.PubMedCentralPubMedCrossRef Davis TM, Beilby J, Davis WA, Olynyk JK, Jeffrey GP, Rossi E, et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2008;31(9):1795–801.PubMedCentralPubMedCrossRef
Metadata
Title
Diabetes and Hemochromatosis
Authors
T. Creighton Mitchell
Donald A. McClain
Publication date
01-05-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 5/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0488-y

Other articles of this Issue 5/2014

Current Diabetes Reports 5/2014 Go to the issue

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

Diabetes Mellitus and Dementia

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

Obesity (J McCaffery, Section Editor)

FTO and Obesity: Mechanisms of Association

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.